A Prospective, Open, Comparative Multicentre Phase II Study for the Evaluation of Irinotecan and Capecitabine Versus Cisplatin and Capecitabine in Advanced Gastric Adenocarcinoma or Gastric-Oesophagal Junction
capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO
2006)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
response rate
Markus Moehler, MD
Principal Investigator
Johannes Gutenberg University Mainz
Germany: Federal Institute for Drugs and Medical Devices
GC-ICE-2003
NCT00675194
October 2003
October 2007
Name | Location |
---|